Trials / Completed
CompletedNCT00821483
A Double Blind Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of Frovatriptan in the Acute Treatment of Migraine
Phase 3 Study to Assess the Efficacy and Safety of Frovatriptan
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 298 (actual)
- Sponsor
- SK Chemicals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is: 1. To compare the efficacy of a single dose of Frovatriptan 2.5 mg with that of placebo in acute treatment of up to one migraine attract 2. To assess recurrence rate between two group 3. To assess the safety and tolerability
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Frovatriptan | 2.5mg, qd |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2008-02-01
- Completion
- 2008-02-01
- First posted
- 2009-01-13
- Last updated
- 2013-04-18
Source: ClinicalTrials.gov record NCT00821483. Inclusion in this directory is not an endorsement.